Time to focus on improving the contraceptive method mix in high HIV prevalence settings and let go of unanswerable questions

Contraception. 2014 Oct;90(4):357-9. doi: 10.1016/j.contraception.2014.05.014. Epub 2014 Jun 2.

Author

Heidi E Jones¹

Affiliation

¹ City University of New York (CUNY) School of Public Health, Hunter College. Electronic address: hjon@hunter.cuny.edu.

PMID: 24993486
DOI: 10.1016/j.contraception.2014.05.014

No abstract available

MeSH terms

Contraception / methods
Contraceptive Agents, Female* / adverse effects
Female
HIV Infections / epidemiology
HIV Infections / etiology*
Humans
Maternal Mortality
Medroxyprogesterone Acetate* / adverse effects
Observational Studies as Topic
Pregnancy
Prevalence
Randomized Controlled Trials as Topic / ethics*

Substances

Contraceptive Agents, Female
Medroxyprogesterone Acetate